விதிறெோரேதினாள் சேவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from விதிறெோரேதினாள் சேவை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In விதிறெோரேதினாள் சேவை Today - Breaking & Trending Today

Unity, on the rebound after catastrophe, shows promising results in early eye disease trial

Unity Biotechnology CEO Anirvan Ghosh, Ph.D. (Unity)
Nearly a year after dropping its lead program and sinking its stock, Unity Biotechnology appears to be coming back on track with positive data in its phase 1 study in patients with advanced vascular eye disease.
The anti-aging biotech said Tuesday its small-molecule inhibitor of Bcl-xL, a senolytic therapeutic, was well tolerated in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD).
Unity shares were up about 9% in early trading Tuesday morning.
The study of UBX1325 was conducted in patients for whom anti–vascular endothelial growth factor (anti-VEGF) therapy was not considered to be beneficial anymore. Anti-VEGF treatments include Roche s Lucentis, Regeneron s Eylea, Novartis Beovu and Roche s Avastin. ....

United States , Roche Lucentis , Roche Avastin , Anirvan Ghosh , Novarti Beovu , Jeffrey Heier , Regeneron Eylea , Retina Research At Ophthalmic Consultants Of Boston , Vitreoretinal Service , Unity Biotechnology , Retina Research , Ophthalmic Consultants , ஒன்றுபட்டது மாநிலங்களில் , ஜெஃப்ரி ஹேஎர் , விழித்திரை ஆராய்ச்சி இல் கண் ஆலோசகர்கள் ஆஃப் போஸ்டன் , விதிறெோரேதினாள் சேவை , ஒற்றுமை உயிரி தொழில்நுட்பவியல் , விழித்திரை ஆராய்ச்சி , கண் ஆலோசகர்கள் ,

Oxurion NV Business and Financial Update

Oxurion NV Business and Financial Update
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United States , Bruxelles Capitale , New York , France General , Region Flamande , Tom Graney , City Of , United Kingdom , Jean Feyen , Ramin Tadayoni , Grace Chang , Dominique Vanfleteren , Arshad Khanani , Sylvie Berrebi Frazer Hall , Los Angeles , Wouter Piepers , Jo Van Ginderachter , Claude Sander , Kathleen Paisley , Citigate Dewe Rogerson , Christopher Brinzey , Yale Law School , Ironwood Pharmaceuticals , Bascom Palmer Eye Institute Angiogenesis , Queen Mary University Of London , University Of Nevada ,

Investegate |Oxurion NV Announcements | Oxurion NV: Oxurion NV Business and Financial Update – FY 2020

First patients dosed in Phase 2 study (‘KALAHARI’) evaluating multiple injections of THR-149, a potent plasma kallikrein inhibitor, for the treatment of DME. Part A data expected by mid-year

THR-687, a pan-RGD integrin antagonist, Phase 2 DME study planned to start by mid-year, following positive Phase 1 data released in 2020

The Company has strengthened the management team with the appointments of Tom Graney, CFA, based in Boston as CFO, Grace Chang M.D., PhD, based in LA as CMO, and Professor Alan Stitt, PhD as CSO.

At the end of December 2020, Oxurion had cash, cash equivalents & investments of €24.8 million, allowing the Company to execute on its business plans through the end of Q3 2021. The Company is in advanced discussions with potential investors in order to increase its cash position. ....

United States , Bruxelles Capitale , New York , France General , Region Flamande , Tom Graney , City Of , United Kingdom , Jean Feyen , Ramin Tadayoni , Grace Chang , Dominique Vanfleteren , Arshad Khanani , Sylvie Berrebi Frazer Hall , Los Angeles , Wouter Piepers , Jo Van Ginderachter , Claude Sander , Kathleen Paisley , Citigate Dewe Rogerson , Christopher Brinzey , Yale Law School , Ironwood Pharmaceuticals , Bascom Palmer Eye Institute Angiogenesis , Queen Mary University Of London , University Of Nevada ,

Oxurion NV Business and Financial Update – FY 2020

First patients dosed in Phase 2 study (‘KALAHARI’) evaluating multiple injections of THR-149, a potent plasma kallikrein inhibitor, for the treatment of DME. Part A data expected by mid-year

THR-687, a pan-RGD integrin antagonist, Phase 2 DME study planned to start by mid-year, following positive Phase 1 data released in 2020

The Company has strengthened the management team with the appointments of Tom Graney, CFA, based in Boston as CFO, Grace Chang M.D., PhD, based in LA as CMO, and Professor Alan Stitt, PhD as CSO.

At the end of December 2020, Oxurion had cash, cash equivalents & investments of €24.8 million, allowing the Company to execute on its business plans through the end of Q3 2021. The Company is in advanced discussions with potential investors in order to increase its cash position. ....

United States , Bruxelles Capitale , New York , France General , Region Flamande , Tom Graney , City Of , United Kingdom , Jean Feyen , Ramin Tadayoni , Grace Chang , Dominique Vanfleteren , Arshad Khanani , Sylvie Berrebi Frazer Hall , Los Angeles , Wouter Piepers , Jo Van Ginderachter , Claude Sander , Kathleen Paisley , Citigate Dewe Rogerson , Christopher Brinzey , Yale Law School , Ironwood Pharmaceuticals , Bascom Palmer Eye Institute Angiogenesis , Queen Mary University Of London , University Of Nevada ,

Oxurion NV Business and Financial Update – FY 2020

Oxurion NV Business and Financial Update – FY 2020
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

United States , Bruxelles Capitale , New York , France General , Region Flamande , Tom Graney , City Of , United Kingdom , Jean Feyen , Ramin Tadayoni , Grace Chang , Dominique Vanfleteren , Arshad Khanani , Sylvie Berrebi Frazer Hall , Los Angeles , Wouter Piepers , Jo Van Ginderachter , Claude Sander , Kathleen Paisley , Citigate Dewe Rogerson , Christopher Brinzey , Yale Law School , Company Annual Report , Ironwood Pharmaceuticals , Bascom Palmer Eye Institute Angiogenesis , Queen Mary University Of London ,